All In Biotech

Drug Trial Radar · NCT07782970

A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

A Randomized, Double-blind, Parallel Group Phase 3 Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) (PERSIST CRSwNP-1)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

218

Planned (sponsor's estimate)

Start

Sep 28, 2026

Primary completion

Mar 6, 2029

Study completion Oct 30, 2029

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to assess the efficacy and safety of GSK5784283 administered as add-on maintenance therapy to participants with CRSwNP.

Conditions

  • Nasal Polyps

Interventions

  • GSK5784283Drug

    GSK5784283 will be administered.

  • PlaceboDrug

    Placebo will be administered.

  • Standard of CareDrug

    Standard of Care will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in total endoscopic nasal polyps (NP) score at Week 52Time frame: Baseline and Week 52
  2. Change from Baseline in mean nasal obstruction score using Verbal Response Scale (VRS) from Week 51 through to Week 52Time frame: Baseline, Weeks 51 to 52 (time - average)

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Tucson, Arizona · Recruiting

  • GSK Investigational Site

    Los Angeles, California · Recruiting

  • GSK Investigational Site

    Louisville, Kentucky · Recruiting

  • GSK Investigational Site

    Tulsa, Oklahoma · Recruiting

  • GSK Investigational Site

    Spartanburg, South Carolina · Recruiting

  • GSK Investigational Site

    Gunma, Japan · Recruiting

  • GSK Investigational Site

    Nagano, Japan · Recruiting

  • GSK Investigational Site

    Nagano, Japan · Recruiting

  • GSK Investigational Site

    San Juan, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.